- CH₣422.53m
- CH₣638.43m
- CH₣448.00m
Brief: Medmix H1 Adjusted EBITDA CHF 43.5 Million
Switzerland's Medmix FY revenue falls 4.8% on weakness in beauty business
Brief: Medmix AG Says HY Revenue At CHF 225.4 Million
Brief: Medmix H1 Adjusted EBITDA CHF 44.9 Million
Swiss stocks - Factors to watch on February 26
Brief: Medmix AG Says FY 2024 Revenue CHF 483.9M
Brief: Medmix FY Adjusted EBITDA CHF 92.5 Million
Brief: Medmix H1 Adjusted EBITDA CHF 46 Million
Swiss stocks - Factors to watch on July 18
Brief: Medmix AG Says In H1, Revenue Of CHF 241.2 Mln, 2.8% Lower Y-o-Y
Brief: Medmix AG FY 2024 Guidance Organic Revenue Growth Of 4% To 6%,
Brief: Medmix FY Adjusted EBITDA Margin 19.1%
Brief: Medmix Announces Sale of Medmix Poland, Removal of Entity From Sanctions List
Europe Research Roundup: Buzzi Unicem, F-Secure, Galenica AG
Brief: Medmix Says Adjusted EBITDA Margin Guidance for FY 2023 Around 22% (Versus. 23%)
Brief: Medmix AG Targets 5% To 7% Growth In Revenue In 2023
Europe Research Roundup: Adidas, Puma, Ubisoft
Brief: Medmix Announces Intention To Sell Entity In Poland And Revises Outlook For FY 2022
Brief: Medmix Says Board Of Directors Nominate Rob Ten Hoedt As Proposed Chairman Of Board